OURA vs S&P 500: Which Stock to Watch

This article is for informational and educational purposes only and does not constitute financial or investment advice. Investing in individual stocks involves risk, including the possible loss of principal. Past performance of any index or security does not guarantee future results. Consult a qualified financial advisor before making investment decisions.

As of early 2025, Oura Health is a private company. OURA stock does not trade on any public stock exchange, and no ticker symbol has been assigned. If you searched for "OURA stock" expecting to find a share price, you arrived at the right place for a clear, evidence-based answer.

The question driving this search is worth taking seriously. You likely own or follow the Oura Ring, heard that the company may be preparing for an IPO (initial public offering — the first time a private company sells shares to the public on a stock exchange), and started wondering whether investing in Oura Health makes more sense than putting that money into the S&P 500. That instinct (buying into a company whose product you use every day) is where plenty of sound investment theses begin.

This article works through the comparison systematically. It covers what Oura Health is as an investable asset, what the S&P 500 offers as the benchmark, a side-by-side metrics table, the bull and bear cases for OURA, a risk breakdown, and a practical guide to what you can actually do right now.

What Is OURA Stock? Understanding Oura Health as an Investment

Oura Health is a private Finnish health technology company best known as the maker of the Oura Ring, a smart ring that tracks sleep, heart rate, and recovery, and one of the most closely watched pre-IPO candidates in consumer health technology.

Who Is Oura Health? The Company Behind the Ring

Oura Health Oy, headquartered in Oulu, Finland with a U.S. presence in San Francisco, builds the hardware and software platform behind the Oura Ring. The company was founded by Petteri Lahtela and operates a dual-revenue model: hardware sales from the Oura Ring ($299–$549 depending on model and material) plus recurring subscription revenue from Oura Membership at $5.99 per month.

As of 2024, Oura Health has surpassed 2 million global users. Its 2023 funding round valued the company at approximately $5 billion. That figure is a private valuation, meaning it was set by investors in a controlled transaction rather than by public market trading. Market capitalization (total market value of a company's outstanding shares, calculated as share price multiplied by shares outstanding) technically applies only to public companies; OURA's $5B figure is a proxy, not a confirmed public price. Actual IPO pricing could come in higher or lower depending on market conditions at the time of listing.

Backing the company are Sequoia Capital, Forerunner Ventures, OMERS Ventures, and UBS. That investor roster signals institutional confidence in OURA's long-term trajectory.

OURA would be classified as a growth stock — a company expected to grow revenue significantly faster than the overall market, typically reinvesting earnings into expansion rather than paying dividends. It operates within the broader digital health sector, which encompasses wearables, telehealth, health apps, and remote patient monitoring. Industry analysts project that market could exceed $800 billion globally by 2030.

Oura Health does not publicly disclose revenue. Analyst estimates place annualized recurring revenue (ARR) at approximately $400–$500 million as of 2024, implying an EV/Revenue multiple (Enterprise Value divided by annual revenue — the standard valuation metric for pre-profitability growth companies) of roughly 10–12x at the $5B private valuation. These are analyst estimates only; actual figures will appear in an S-1 filing if and when the company pursues a public listing.

As of early 2025, Oura Health has not filed an S-1 registration statement with the SEC and no OURA ticker symbol exists. To become publicly tradable, Oura Health would need to complete either an IPO or a SPAC (Special Purpose Acquisition Company) merger, both of which are pathways to public listing, though no SPAC deal involving Oura Health has been reported. Investors who want early notice of a filing can set a search alert on SEC EDGAR for Oura Health, since an S-1 registration is the first concrete public signal that a listing is approaching.

Under GICS (Global Industry Classification Standard), Oura Health would sit within the Health Technology sector, specifically the Medical Devices or Consumer Health sub-industry, the same classification as DexCom and comparable health wearables companies.

The Oura Ring: The Product That Drives the Investment Thesis

If you already own an Oura Ring, you know the product. The company behind it is a different story.

The Oura Ring is a titanium smart ring worn on the finger that tracks sleep stages, resting heart rate, HRV (heart rate variability — the variation in time between heartbeats, a key indicator of stress and recovery), SpO2, skin temperature, and daily activity. The ring's form factor differentiates it from wrist-worn wearables; its sleep tracking in particular is widely regarded as best-in-class among consumer devices. NBA teams, biohackers, and health professionals have adopted it alongside mainstream consumers.

The global wearable technology market was valued at approximately $60–70 billion in 2024 and is projected to grow at 14–16% CAGR through 2030, according to data from Grand View Research and Statista. Smart rings represent a fast-growing niche within that broader category. Samsung Galaxy Ring's 2024 launch validates the segment commercially, and OURA is not building a market alone.

OURA's competitive landscape includes Apple Watch (estimated 30%+ global wearable market share), WHOOP, Garmin, Samsung Galaxy Ring, and the Fitbit brand now owned by Google/Alphabet. WHOOP, Inc., a Boston-based health wearables company operating a subscription-only model, was valued at $3.6 billion as of its last reported 2021 funding round. OURA's premium over WHOOP's valuation reflects investors assigning more value to OURA's larger consumer base and hardware-plus-subscription hybrid model.

The question for investors is whether the business model behind this product is strong enough to outperform the S&P 500 over the long run.

What Is the S&P 500? The Benchmark Every Investment Must Beat

The S&P 500 is a stock market index tracking the 500 largest publicly traded U.S. companies by market capitalization, maintained by S&P Dow Jones Indices. It serves as a benchmark index, a standard against which investment performance is measured, covering approximately 80% of total U.S. equity market value. Its largest holdings as of 2024 include Apple (AAPL), Microsoft (MSFT), NVIDIA (NVDA), Amazon (AMZN), and Meta (META).

For any investment to justify its risk, it needs to beat approximately 10% per year, which is the S&P 500's long-run average. The index has returned approximately 10% annually in nominal terms since its 1957 inception, or roughly 7% after adjusting for inflation, based on S&P Dow Jones Indices data. Over the 10-year period from 2014 to 2024, it returned approximately 13% per year on a CAGR basis, roughly tripling an initial investment. Past performance does not predict future results.

You cannot buy the S&P 500 directly. Investors access index exposure through ETFs (exchange-traded funds, baskets of securities that trade on a stock exchange like a single share). SPY (SPDR S&P 500 ETF Trust), issued by State Street Global Advisors, is the world's largest ETF by assets under management at over $500 billion, with an expense ratio of 0.0945%. Cost-conscious investors often prefer VOO (Vanguard S&P 500 ETF) at an expense ratio of 0.03%; both track the same index, but VOO's lower annual fee compounds meaningfully over long holding periods.

The S&P 500's historical volatility profile runs approximately 15% annualized standard deviation, and its breadth across 500 companies gives it a structural advantage over any single stock. According to the SPIVA U.S. Scorecard, approximately 90% of actively managed U.S. equity funds underperform the S&P 500 over any 15-year period. That figure explains why beating this index is genuinely difficult, and why it serves as the right comparison point for any individual stock, including OURA.

OURA vs S&P 500: Side-by-Side Comparison

The table below presents OURA and the S&P 500 across the metrics that matter most to a retail investor. The single most consequential row is Current Tradability, because one of these investments can be bought today, and one cannot.

OURA vs S&P 500 Stock: Key Metrics Compared

*Beta estimated based on comparable HealthTech companies including DexCom and Teladoc. Actual beta is calculable only after public listing. **OURA valuation is a private funding round figure. Actual IPO market cap may differ significantly from this figure. This table is for informational purposes only and does not constitute investment advice.

Every metric in this table becomes directly comparable only if and when Oura Health completes a public listing. The S&P 500 via SPY or VOO can be purchased in minutes through any brokerage account. OURA cannot. Risk level, expected return, and beta are all forward-looking estimates for OURA, based on comparable companies rather than on OURA's own public trading history, which does not yet exist.

Is OURA a Good Investment? Bull Case and Bear Case

When people ask whether "OURA is a good investment," they usually mean one of two things: whether the Oura Ring is worth buying as a health device, or whether Oura Health is worth buying as a stock. This section addresses the second question.

Whether OURA represents a sound stock investment depends on which of the following cases you find more convincing.

The Bull Case for OURA Stock

The bull case for OURA rests on three interlocking arguments: a large and growing addressable market, a subscription revenue model with built-in compounding, and institutional validation from tier-1 investors.

The global wearable health technology market is projected to reach $150 billion or more by 2028 according to analyst projections. OURA operates at the intersection of that market and the broader digital health sector. A company that has already crossed 2 million paying users, each generating hardware revenue plus monthly subscription fees, has demonstrated real demand rather than just a product concept.

Oura Membership at $5.99 per month generates recurring revenue that compounds as the user base grows. Hardware companies without subscription models are vulnerable to slowing upgrade cycles; OURA's model reduces that vulnerability. Analyst estimates place ARR at $400–$500 million as of 2024 (Oura Health does not publicly disclose financials; these are estimates only), implying an EV/Revenue multiple of approximately 10–12x at the $5B private valuation, within the range of comparable health tech companies at similar growth stages.

OURA's institutional backing from Sequoia Capital and Forerunner Ventures indicates that sophisticated investors with access to private financials have underwritten the $5B valuation. That private valuation exceeds WHOOP's $3.6B as of its last reported 2021 funding round, with the premium reflecting OURA's broader consumer appeal and larger user base.

DexCom (DXCM) represents the most instructive comparable for the bull case. DexCom, a publicly traded continuous glucose monitoring company, IPO'd in 2005 at approximately $3.35 per share (split-adjusted) and grew to a $40 billion-plus market cap by 2021. DexCom is cited here as a comparable reference only, not a direct equivalent; it operates in glucose monitoring rather than general wellness tracking. The structural similarity is the hardware-plus-subscription health data model. Historical precedent from comparable health tech companies suggests that model has the potential to generate returns that outperform the S&P 500 over a long holding period when the underlying product achieves mainstream adoption.

Samsung Galaxy Ring's 2024 launch also validates the smart ring category commercially, reducing the risk that OURA's form factor remains a niche segment.

The Bear Case for OURA Stock

The bear case for OURA is grounded in four specific risks that any investor should weigh before taking a position: competitive threat from Apple, the cautionary precedent set by Fitbit, pre-profitability fragility, and the unknown quality of financial disclosures not yet available.

Apple Watch holds an estimated 30%+ share of the global wearable market and continues expanding its health-monitoring capabilities, including ECG, blood oxygen, and crash detection features that overlap directly with Oura Ring capabilities. Apple's device ecosystem scale is a structural competitive risk that OURA cannot replicate through a single product, however well-designed.

Fitbit IPO'd in June 2015 at $20 per share, briefly reached approximately $51, then declined steadily before being acquired by Google in January 2021 at $7.35 per share. Fitbit is cited here as a comparable reference only, not a direct equivalent. Consumer enthusiasm at IPO does not guarantee long-term stock outperformance versus the S&P 500.

OURA is not yet profitable. The P/E ratio, a company's share price divided by its earnings per share, is the most common public stock valuation metric, but since OURA is pre-profitability, it will likely be not meaningful (N/M) at IPO. Revenue growth without earnings creates valuation fragility, particularly if post-IPO growth targets are missed. Health technology stocks as a sector have historically carried betas of 1.3–1.8x, meaning they swing 30–80% more than the overall market in both directions. DexCom and Teladoc have each experienced single-day price drops of 20–40%+ on earnings disappointments, and this volatility profile would likely apply to OURA post-IPO based on comparable company behavior.

No public financial statements exist for Oura Health. The S-1 filing, when it arrives, may reveal customer acquisition costs, churn rates, or unit economics that are less favorable than current analyst estimates assume. Investors are making pre-IPO judgments without access to audited data.

The bull and bear cases above are why OURA is best evaluated against the S&P 500 as a benchmark rather than in isolation.

OURA vs S&P 500: Risk Profile Breakdown

OURA and the S&P 500 carry fundamentally different risk profiles. One is a single pre-profit growth-stage stock in a volatile sector; the other is a diversified index of 500 established companies.

Concentration risk, the elevated danger of holding a large portion of a portfolio in a single security, is the defining structural difference between these two options. If OURA declines 50% after its IPO (a pattern Fitbit followed over several years), a concentrated OURA position absorbs that full 50% loss. A diversified S&P 500 portfolio cannot fall 50% unless the entire U.S. economy collapses. Financial advisors generally recommend limiting any single speculative stock to no more than 5–10% of a total investment portfolio.

The statistics on individual stock performance are worth examining directly. According to the SPIVA U.S. Scorecard, approximately 90% of actively managed U.S. equity funds underperform the S&P 500 over any 15-year period. Research by academic Hendrik Bessembinder shows that over the long run, a majority of individual stocks underperform Treasury bills, with a small number of exceptional outliers generating most of the equity market's excess returns. OURA, as a single health technology stock, would face these same statistical odds unless it proves to be one of the rare outliers that justify concentrated exposure.

Beta and the Sharpe Ratio give investors two quantitative tools for sizing up this risk difference. Beta, a measure of a stock's volatility relative to the market where 1.0 means it moves exactly in line with the S&P 500, runs at exactly 1.0 for the index by definition. Comparable HealthTech growth companies like DexCom and Teladoc have historically carried betas of 1.3–1.8x, meaning 30–80% more price movement than the broader market in both directions. The Sharpe Ratio, which measures how much return an investment generates per unit of risk taken, gives the S&P 500 a long-term reading of approximately 0.5–0.6, which sets the benchmark a concentrated OURA position would need to match or exceed to justify its added volatility.

Portfolio diversification, spreading investments across multiple securities, sectors, and asset classes to reduce the impact of any single failure, is the structural advantage SPY holds over any single stock. Owning SPY provides exposure to 500 companies across 11 sectors simultaneously, eliminating company-specific risk while retaining broad market exposure.

Risk Spectrum: Four Investment Options Compared

How to Invest in OURA and the S&P 500 Right Now

The mechanics for investing in each option differ significantly. One is available today through any standard brokerage account; the other requires a monitoring strategy while waiting for a public listing.

How to Invest in the S&P 500 Today

Investing in the S&P 500 requires four steps, executable through any standard brokerage platform:

1. Open a brokerage account with any major broker such as Fidelity, Schwab, Vanguard, or similar.
2. Search for SPY, VOO, or IVV in the investment search tool.
3. Purchase shares. No minimum investment applies beyond the share price; fractional shares are available on most platforms for as little as $1.
4. Hold long-term. The S&P 500's historical returns compound most effectively over 10+ year periods.

SPY (SPDR S&P 500 ETF Trust) carries an expense ratio of 0.0945% and is the most liquid ETF in the world by daily trading volume, making it the standard choice for institutional and retail investors alike. VOO (Vanguard S&P 500 ETF), with an expense ratio of 0.03%, is the lower-cost alternative preferred by most long-term buy-and-hold investors. Both track the same index.

Investors who want health technology sector exposure while OURA remains private can consider two sector ETFs as indirect proxies. XLV (Health Care Select Sector SPDR ETF), with an expense ratio of approximately 0.09%, tracks all healthcare companies in the S&P 500 including medical devices and health tech firms. IHI (iShares U.S. Medical Devices ETF, expense ratio approximately 0.41%) focuses specifically on medical device companies; it holds DexCom, Intuitive Surgical, and Boston Scientific, placing it closer to OURA's segment than XLV. Neither ETF holds OURA stock. OURA is a private company and not eligible for ETF inclusion. These are proxy options, not substitutes for OURA shares.

How to Get OURA Exposure Before the IPO

As of early 2025, OURA stock cannot be purchased through any standard brokerage account. Oura Health has not filed an S-1 registration statement with the SEC, which is required before any U.S. public listing. Three tiers of access exist depending on your investor status:

Tier 1: Accredited investors only

Eligibility: net worth exceeding $1 million (excluding primary residence) or annual income exceeding $200,000.

Secondary market platforms such as EquityZen or Forge Global allow accredited investors to purchase pre-IPO shares from existing employees and early investors. These transactions carry illiquidity, no SEC disclosure requirements, valuation opacity, and lock-up periods after any eventual IPO. Pre-IPO investing is distinct from buying shares on listing day; it means acquiring shares before the company files or completes its public offering.

Tier 2: All investors (indirect exposure)

Eligibility: any investor with a standard brokerage account.

XLV and IHI sector ETFs provide exposure to comparable publicly traded health technology companies while OURA remains private. These ETFs do not hold OURA directly and are not substitutes for OURA stock.

Tier 3: All investors (watchlist)

Eligibility: any investor.

Set a search alert for Oura Health on the SEC's EDGAR database. An S-1 registration filing is the first public signal that an IPO is approaching. Also monitor for investment bank underwriter announcements and Oura Health press releases about capital markets activity. Opening your brokerage account before any IPO announcement ensures you can act quickly if and when shares become available.

OURA vs S&P 500: Which Should You Choose?

OURA and the S&P 500 are not a binary choice. They serve different roles in a portfolio and can coexist. The right answer depends on your risk tolerance, time horizon, and conviction in the health technology market.

Conservative investors investing savings they cannot afford to lose, prioritizing diversification over growth potential, or working with a time horizon under five years will find the S&P 500 via SPY or VOO the more defensible choice. It has historically returned approximately 10% annually in nominal terms, carries built-in diversification across 500 companies, and can be bought or sold instantly through any brokerage.

Growth investors with high risk tolerance holding conviction in the long-term trajectory of health wearables, a time horizon of five or more years, and the financial cushion to absorb a significant loss if OURA's IPO or early public performance disappoints have reason to watch OURA closely. The investment case rests on what the S-1 disclosures reveal: revenue growth trajectory, profitability timeline, and whether the IPO offering price justifies the concentrated risk.

A balanced approach combines both options. Place 90–95% of your equity allocation in a diversified index ETF (SPY or VOO), then reserve a satellite position of 5–10% for OURA at IPO. Financial advisors generally recommend no more than 5–10% of a total portfolio in any single speculative stock. For a pre-IPO company with no public financial history, a position in the 2–5% range is a conservative implementation of that principle. This is general educational information, not personalized financial advice.

Yes, you can hold OURA stock and an S&P 500 ETF simultaneously. The two are not mutually exclusive. Many investors hold a large core position in an index ETF alongside smaller speculative allocations in individual growth stocks; this structure is called a core-satellite portfolio strategy.

OURA is best evaluated as a long-term investment thesis covering five or more years. It is a growth-stage company not yet profitable, meaning near-term price swings are expected while the business scales. The S&P 500 has historically rewarded any holding period over 10 years and, based on historical data, has never lost value over any rolling 20-year period.

Before committing capital at IPO, evaluate four signals in the S-1 when it is filed: revenue figures against analyst estimates, the EV/Revenue multiple at the offering price relative to peers, the profitability timeline disclosed by management, and the competitive landscape at the time of listing.

OURA is among the most-watched potential IPOs in health technology. The S-1 filing will be the moment investors can finally evaluate the business on publicly disclosed financial data, and the moment this comparison moves from a forward-looking framework to a live investment decision.

This article is for informational and educational purposes only and does not constitute financial or investment advice. Investing in individual stocks involves risk, including the possible loss of principal. Past performance of any index or security does not guarantee future results. Consult a qualified financial advisor before making investment decisions.

Frequently Asked Questions: OURA Stock and S&P 500

Is Oura Health publicly traded?

No. As of early 2025, Oura Health is a private company. OURA stock does not trade on any public stock exchange, and no ticker symbol has been assigned. The company has not filed an S-1 registration statement with the SEC. If Oura Health goes public, it would list on NASDAQ or NYSE. Monitor SEC EDGAR for an S-1 filing as the earliest signal of an imminent IPO.

What is the OURA stock ticker symbol?

OURA does not have a stock ticker symbol. The company has not completed an IPO, and no exchange has assigned a ticker. A ticker would be designated at the time of public listing. To receive early notice, set a search alert for Oura Health on SEC EDGAR at sec.gov, since an S-1 registration is the first publicly available IPO signal.

What is Oura Health's valuation?

Oura Health's most recent reported valuation was approximately $5 billion, based on its 2023 funding round. This is a private funding round valuation, not a public market capitalization. At analyst-estimated annualized recurring revenue of $400–$500 million (unconfirmed; Oura Health does not publicly disclose financials), this implies an EV/Revenue multiple of approximately 10–12x. Actual IPO pricing may differ meaningfully from this private valuation.

What are OURA's main competitors?

OURA's main competitors in the health wearables market include Apple Watch (estimated 30%+ global wearable market share), WHOOP, Garmin, Samsung Galaxy Ring, and the Fitbit brand now owned by Google/Alphabet. Apple Watch represents the most significant competitive risk due to its ecosystem scale and expanding health-monitoring features that overlap with Oura Ring capabilities.

How has the S&P 500 performed over the last 10 years?

Over the 10-year period from 2014 to 2024, the S&P 500 returned approximately 13% per year on a compound annual growth rate basis, roughly tripling an initial investment. The long-run historical average since 1957 is approximately 10% annually in nominal terms, according to S&P Dow Jones Indices data. Past performance does not predict future results.

Is it better to buy individual stocks or index funds?

For most retail investors, diversified index funds tracking the S&P 500 have historically outperformed individual stock picking over the long run. According to the SPIVA U.S. Scorecard, approximately 90% of active fund managers underperform the S&P 500 over 15-year periods. Exceptional individual companies such as Amazon, DexCom, and Apple before its S&P 500 inclusion have dramatically outperformed the index. The trade-off: index funds deliver market returns with lower risk, while individual stocks offer potentially higher returns with substantially higher variance and the risk of permanent loss.

What ETFs track health technology stocks?

Two relevant options for health technology sector exposure are XLV (Health Care Select Sector SPDR ETF, expense ratio approximately 0.09%), which tracks healthcare companies across the S&P 500 including medical devices and health tech, and IHI (iShares U.S. Medical Devices ETF, expense ratio approximately 0.41%), which focuses on medical device companies such as DexCom and Intuitive Surgical. Neither ETF holds OURA stock directly; OURA is a private company ineligible for ETF inclusion. Both are proxy options only.

Can I buy OURA stock before the IPO?

Not through standard brokerage accounts. Accredited investors (net worth exceeding $1 million excluding primary residence, or annual income exceeding $200,000) may access pre-IPO shares via secondary market platforms such as EquityZen or Forge Global, though these carry illiquidity and lock-up period risks. All investors can gain indirect health technology sector exposure via XLV or IHI ETFs. Setting an alert on SEC EDGAR for Oura Health's S-1 filing is the earliest available IPO signal.

What is the OURA stock price prediction?

No reliable price prediction is possible for a pre-IPO company before it begins trading publicly. Comparable health tech IPOs provide reference points: Fitbit priced at $20 per share at its 2015 IPO before declining to a $7.35 acquisition price; DexCom priced at approximately $3.35 per share (split-adjusted) at its 2005 IPO before growing to a $40 billion-plus market cap by 2021. Actual OURA IPO pricing will depend on market conditions, investor demand, and underwriter valuations at the time of listing.

All FAQ answers are for informational purposes only and do not constitute investment advice.